对《多国共识：德谷胰岛素/门冬胰岛素起始胰岛素治疗（IDegAsp）》的勘误
Correction to: Multinational Consensus: Insulin Initiation with Insulin Degludec/Aspart (IDegAsp).
作者信息
Kalra Sanjay, Atkin Stephen, Cervera Antonio, Das Ashok Kumar, Demir Ozgur, Demir Tevfik, Fariduddin Md, Vo Khoa Tuan, Ku Bon Jeong, Kumar Ajay, Latif Zafar A, Malek Rachid, Matawaran Bien J, Mehta Roopa, Tran Nam Quang, Panelo Araceli, Ruder Sundeep, Saldana Joel Rodriquez, Shaikh Khalid A, Shakya Amit, Shrestha Dina, Unnikrishnan A G
机构信息
Department of Endocrinology, Bharti Hospital Karnal, Karnal, India.
Department of Medicine, Weill Cornell Medical College, Doha, Qatar.
出版信息
Adv Ther. 2018 Jul;35(7):937-938. doi: 10.1007/s12325-018-0728-7.
Abstract
Unfortunately, the fifth author name was incorrectly published in the original publication. The correct name should read as 'Ozgur Demir'.
摘要
不幸的是，第五位作者的名字在原出版物中被错误发表了。正确的名字应该是“奥兹古尔·德米尔”。
相似文献
1
Correction to: Multinational Consensus: Insulin Initiation with Insulin Degludec/Aspart (IDegAsp).对《多国共识：德谷胰岛素/门冬胰岛素起始胰岛素治疗（IDegAsp）》的勘误
Adv Ther. 2018 Jul;35(7):937-938. doi: 10.1007/s12325-018-0728-7.
2
Pragmatic use of insulin degludec/insulin aspart co-formulation: A multinational consensus statement.德谷胰岛素/门冬胰岛素共混制剂的实用应用：一项跨国共识声明。
Indian J Endocrinol Metab. 2016 Jul-Aug;20(4):542-5. doi: 10.4103/2230-8210.182980.
3
Multinational Consensus: Insulin Initiation with Insulin Degludec/Aspart (IDegAsp).多国共识：德谷胰岛素门冬胰岛素（IDegAsp）起始胰岛素治疗。
Adv Ther. 2018 Jul;35(7):928-936. doi: 10.1007/s12325-018-0712-2. Epub 2018 May 23.
4
Practical use of insulin degludec/insulin aspart in a multinational setting: beyond the guidelines.在跨国环境中实际使用德谷胰岛素/门冬胰岛素：超越指南。
Diabetes Obes Metab. 2020 Nov;22(11):1961-1975. doi: 10.1111/dom.14128. Epub 2020 Aug 12.
5
The Clinical Role of Insulin Degludec/Insulin Aspart in Type 2 Diabetes: An Empirical Perspective from Experience in Australia.德谷胰岛素/门冬胰岛素在2型糖尿病中的临床作用：来自澳大利亚经验的实证观点
J Clin Med. 2020 Apr 11;9(4):1091. doi: 10.3390/jcm9041091.
6
Original paper: Efficacy and safety analysis of insulin degludec/insulin aspart compared with biphasic insulin aspart 30: A phase 3, multicentre, international, open-label, randomised, treat-to-target trial in patients with type 2 diabetes fasting during Ramadan.原始论文：在进行开斋节斋戒的 2 型糖尿病患者中，对比地特胰岛素/门冬胰岛素与双时相门冬胰岛素 30 的疗效和安全性分析：一项 3 期、多中心、国际性、开放性标签、随机、靶向治疗的临床试验。
Diabetes Res Clin Pract. 2018 Jan;135:218-226. doi: 10.1016/j.diabres.2017.11.027. Epub 2017 Nov 26.
7
Insulin degludec/insulin aspart vs biphasic insulin aspart 30 twice daily in Japanese patients with type 2 diabetes: A randomized controlled trial.德谷胰岛素/门冬胰岛素与门冬胰岛素30每日两次治疗日本2型糖尿病患者的随机对照试验
J Diabetes Investig. 2017 Mar;8(2):210-217. doi: 10.1111/jdi.12569. Epub 2016 Oct 7.
8
Insulin degludec/insulin aspart in Japanese patients with type 1 diabetes mellitus: Distinct prandial and basal glucose-lowering effects.德谷胰岛素/门冬胰岛素用于日本1型糖尿病患者：独特的餐时和基础降糖作用
J Diabetes Investig. 2016 Jul;7(4):574-80. doi: 10.1111/jdi.12461. Epub 2016 Feb 4.
9
Insulin degludec/insulin aspart administered once daily at any meal, with insulin aspart at other meals versus a standard basal-bolus regimen in patients with type 1 diabetes: a 26-week, phase 3, randomized, open-label, treat-to-target trial.每日一次在任意一餐中给予德谷胰岛素/门冬胰岛素，其他餐次给予门冬胰岛素，与 1 型糖尿病患者的标准基础-餐时胰岛素方案相比：一项 26 周、3 期、随机、开放标签、以目标为导向的试验。
Diabetes Care. 2012 Nov;35(11):2174-81. doi: 10.2337/dc11-2503. Epub 2012 Aug 28.
10
Comparison of the efficacy and safety of once-daily insulin degludec/insulin aspart (IDegAsp) and long-acting second-generation basal insulin (insulin degludec and insulin glargine 300 units/mL) in insulin-naïve Japanese adults with type 2 diabetes: a pilot, randomized, controlled study.在胰岛素初治的日本 2 型糖尿病成人中，每日一次胰岛素地特胰岛素/门冬胰岛素（IDegAsp）与长效第二代基础胰岛素（地特胰岛素和甘精胰岛素 300 单位/毫升）的疗效和安全性比较：一项先导、随机、对照研究。
Endocr J. 2019 Aug 29;66(8):745-752. doi: 10.1507/endocrj.EJ19-0179. Epub 2019 Jul 12.
Zotero 插件